Julian Gangolli

Julian Gangolli


Mr. Gangolli has a well-established track record, having served as President of the North American Pharmaceutical division of Allergan, Inc. for 11 years where he was a member of the Executive Committee of Allergan and was responsible for a 1,400-person commercial operation with sales exceeding $3.8 billion in 2014. Mr. Gangolli most recently served as President, North America of Greenwich Biosciences, a GW Pharmaceuticals PLC (NASDAQ: GWPH) Company, where he was responsible for building out the U.S. commercial infrastructure and spearheading the launch of its lead therapeutic product Epidiolex®.

Mr. Gangolli joined Allergan in 1998 and was a senior member of the management team that transformed the company into one of the leading specialty pharmaceutical companies in the United States. As a member of the Allergan Executive Committee, he was part of the select team that executed the sale of Allergan to Actavis in 2015.

In addition to joining the Naegis Board of Directors, Mr. Gangolli currently serves as a Director on the Boards of Outlook Therapeutics Inc., Revance Therapeutics (NASDAQ: RVNC) and Krystal Biotech (NASDAQ: KRYS).

We use cookies to improve our website. By continuing to use this website, you are giving consent to cookies being used. More details…